Hospital
Galen of Florida, INC.
Galen of Florida, INC. was paid $7.15M by Medicaid between Jan 2018 and Dec 2024, across 126 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoGALEN OF FLORIDA, INC.
ST PETERSBURG, FL 33710
ST PETERSBURG, FL 33710
33aNPI1518911031assigned 05/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.15M
24GClaims321,576
24DCodes billed126
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#69 of 163
Median peer was paid$4.77M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,561 | $258K | |
| 2019 | 60,727 | $760K | |
| 2020 | 47,144 | $690K | |
| 2021 | 67,080 | $1.57M | |
| 2022 | 68,122 | $2.00M | |
| 2023 | 42,843 | $1.34M | |
| 2024incomplete | 15,099 | $530K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 25,184 | 22,658 | $1.90M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 24,116 | 20,203 | $1.58M |
| 80053 | Comprehensive metabolic panel | 7.2% | 20,572 | 16,128 | $517K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 1,845 | 1,625 | $376K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 3,172 | 2,633 | $372K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.5% | 1,801 | 1,577 | $250K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 3,403 | 3,162 | $246K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 3,855 | 3,038 | $236K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.8% | 1,385 | 1,292 | $131K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 3,815 | 3,214 | $126K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 8,942 | 7,595 | $109K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 1,597 | 1,170 | $81K |
114 more codes
| 93975 | <1% | 3,726 | $68K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 989 | $66K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 234 | $62K |
| 87070 | <1% | 2,274 | $60K | |
| 76801 | <1% | 2,764 | $58K | |
| 81001 | <1% | 14,481 | $56K | |
| 84702 | <1% | 3,986 | $54K | |
| G0378 | Hospital observation service, per hour | <1% | 3,175 | $53K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,025 | $47K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,888 | $40K |
| 87210 | <1% | 3,586 | $36K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,213 | $33K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,494 | $32K |
| 87040 | <1% | 1,840 | $32K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 507 | $31K |
| 81003 | <1% | 4,893 | $31K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,396 | $30K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,727 | $30K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 395 | $26K |
| 81025 | <1% | 5,680 | $26K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,194 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 599 | $21K |
| 76830 | Ultrasound, transvaginal | <1% | 1,107 | $20K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 252 | $17K |
| 87077 | <1% | 1,580 | $15K | |
| 85027 | <1% | 24,709 | $14K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 317 | $14K |
| 73130 | <1% | 676 | $14K | |
| 73610 | <1% | 634 | $13K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,339 | $13K |
| A9270 | Non-covered item or service | <1% | 5,507 | $12K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 286 | $12K |
| 73630 | <1% | 766 | $12K | |
| 73562 | <1% | 775 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,665 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,218 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 270 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,194 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 545 | $8K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,346 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,056 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,213 | $7K |
| 73030 | <1% | 354 | $6K | |
| 86900 | <1% | 2,364 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,549 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 513 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,385 | $5K |
| 85610 | <1% | 3,941 | $5K | |
| 84484 | <1% | 6,382 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 105 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 431 | $3K |
| 87280 | <1% | 122 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 752 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,218 | $3K |
| 73110 | <1% | 204 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,007 | $2K |
| S0028 | Injection, famotidine, 20 mg | <1% | 537 | $2K |
| 83690 | <1% | 6,330 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 359 | $2K |
| 85730 | <1% | 1,659 | $2K | |
| 87186 | <1% | 1,198 | $1K | |
| 74021 | <1% | 70 | $1K | |
| 83735 | <1% | 2,254 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,003 | $1K |
| 72110 | <1% | 35 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 356 | $1K |
| 93971 | <1% | 121 | $1K | |
| 86850 | <1% | 608 | $985.24 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 52 | $973.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 190 | $965.22 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,293 | $891.16 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,270 | $736.93 |
| 83880 | <1% | 1,029 | $730.52 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 559 | $630.75 |
| 85379 | <1% | 732 | $544.39 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51 | $505.95 |
| 76818 | <1% | 19 | $432.53 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 439 | $384.74 |
| 73502 | <1% | 31 | $366.03 | |
| 90715 | <1% | 252 | $320.87 | |
| 73080 | <1% | 15 | $272.01 | |
| 83605 | <1% | 1,180 | $229.25 | |
| 96376 | <1% | 1,119 | $225.46 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,689 | $196.19 |
| 86901 | <1% | 2,361 | $189.45 | |
| J3490 | Unclassified drugs | <1% | 131 | $181.34 |
| J1815 | Injection, insulin, per 5 units | <1% | 66 | $181.34 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 300 | $167.09 |
| 74018 | <1% | 15 | $138.61 | |
| 84145 | <1% | 69 | $129.68 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,034 | $105.13 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 60 | $90.67 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 18 | $90.67 |
| 80061 | Lipid panel | <1% | 99 | $85.77 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 784 | $64.57 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,850 | $4.55 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,906 | $1.54 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 259 | $1.22 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 266 | $0.00 |
| 76376 | 0% | 14 | $0.00 | |
| 85007 | 0% | 34 | $0.00 | |
| 84100 | 0% | 42 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 18 | $0.00 |
| S0030 | Injection, metronidazole, 500 mg | 0% | 20 | $0.00 |
| 72100 | 0% | 13 | $0.00 | |
| 82150 | 0% | 68 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 14 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 44 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 12 | $0.00 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 0% | 14 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 18 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 29 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 19 | $0.00 |
| 87147 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARUSO, MARIA (CFO)
| Provider | Location | Paid |
|---|---|---|
| West Florida - PPH, LLC | South Pasadena, FL | $992K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.